摘要
目的观察低分子肝素治疗进展性脑梗死的临床效果。方法分析24例应用低分子肝素治疗的进展性脑梗死患者并与未应用低分子肝素治疗的25例做分析对照,比较两组治疗前后纤维蛋白原和神经功能缺损评分。结果两组临床治愈率分别为87.5%和65%,统计学比较有显著差异(P<0.05)。治疗组在治疗前后纤维蛋白原变化有显著差异(P<0.01)。结论低分子肝素治疗进展性脑梗死临床疗效确切、安全可靠。
Objective:To investigate the clinical effect of low molecular weigh heparin on patients with progressive stroke.Methods:24 patients with progressive stroke were treated with low molecular weight heparin,and 25 patients in control group were treated without low molecular weight heparin.The concentration of plasma fibrinogen and the score of neurologic impairment in experiment group were compared with control group.Results:The cute rates were 87.5% in treatment group and 65% in control group,the difference was significant (P<0.05).In addition,the difference of plasma fibrinogen between two groups was significant(P<0.01).Conclusion:Low molecular weight heparin is safe and effective in treating progressive stroke.
出处
《临床医药实践》
2005年第7期496-498,共3页
Proceeding of Clinical Medicine
关键词
低分子肝素
进展性脑梗死
纤维蛋白原
low molecular weight heparin
progressive stroke
fibrinogen